320 related articles for article (PubMed ID: 27439470)
41. Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in Germany.
Iftner T; Neis KJ; Castanon A; Landy R; Holz B; Woll-Herrmann A; Iftner A; Staebler A; Wallwiener D; Hann von Weyhern C; Neis F; Haedicke-Jarboui J; Martus P; Brucker S; Henes M; Sasieni P
J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30355760
[TBL] [Abstract][Full Text] [Related]
42. PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort.
Kang Y; Sun P; Mao X; Dong B; Ruan G; Chen L
J Gynecol Oncol; 2019 May; 30(3):e29. PubMed ID: 30887754
[TBL] [Abstract][Full Text] [Related]
43. Comparison of analytical and clinical performances of the digene HC2 HPV DNA assay and the INNO-LiPA HPV genotyping assay for detecting high-risk HPV infection and cervical neoplasia among HIV-positive African women.
Ngou J; Gilham C; Omar T; Goumbri-Lompo O; Doutre S; Michelow P; Kelly H; Didelot MN; Chikandiwa A; Sawadogo B; Delany-Moretlwe S; Meda N; Costes V; Mayaud P; Segondy M
J Acquir Immune Defic Syndr; 2015 Feb; 68(2):162-8. PubMed ID: 25394189
[TBL] [Abstract][Full Text] [Related]
44. Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening.
Ejegod DM; Lagheden C; Bhatia R; Pedersen H; Boada EA; Sundström K; Cortés J; Josë FXB; Cuschieri K; Dillner J; Bonde J
BMC Cancer; 2020 May; 20(1):396. PubMed ID: 32375689
[TBL] [Abstract][Full Text] [Related]
45. Human papillomavirus oncogenic mRNA testing for cervical cancer screening: baseline and longitudinal results from the CLEAR study.
Reid JL; Wright TC; Stoler MH; Cuzick J; Castle PE; Dockter J; Getman D; Giachetti C
Am J Clin Pathol; 2015 Sep; 144(3):473-83. PubMed ID: 26276778
[TBL] [Abstract][Full Text] [Related]
46. Sensitivity of APTIMA HPV E6/E7 mRNA test in comparison with hybrid capture 2 HPV DNA test for detection of high risk oncogenic human papillomavirus in 396 biopsy confirmed cervical cancers.
Basu P; Banerjee D; Mittal S; Dutta S; Ghosh I; Chowdhury N; Abraham P; Chandna P; Ratnam S
J Med Virol; 2016 Jul; 88(7):1271-8. PubMed ID: 26693677
[TBL] [Abstract][Full Text] [Related]
47. Performance of Aptima-HPV in the cervical cancer screening program of Portugal: a cost-analysis.
Figueiredo D; Ribeiro I; Penedones A; Mendes D; Alves C; Batel-Marques F; da Silva DP
BMC Womens Health; 2023 Mar; 23(1):96. PubMed ID: 36894908
[TBL] [Abstract][Full Text] [Related]
48. [Evaluation of gene chip technology for high risk type human papillomavirus in cervical cancer screening].
Li RZ; Shi JF; Zhou QZ; Wu RF; Li N; Wu LN; Zhou YQ; Wang Q; Liu ZH; Liu B; Qiao YL
Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(5):307-11. PubMed ID: 16677522
[TBL] [Abstract][Full Text] [Related]
49. Comparison of a Newly Developed HPV Genotyping Assay (Mojin HPV Kit) with Cobas 4800 HPV Test for Detection of High-Risk HPV in Specimens Collected in SurePath Solution.
Yang WW; Wang ZG; Chen GF; Shi JF; Chen J; Ma QH; Zhou J; Mao XD; Liu C; Yao XM
Clin Lab; 2018 Mar; 64(3):387-391. PubMed ID: 29739098
[TBL] [Abstract][Full Text] [Related]
50. Screening outcome of HPV-vaccinated women: Data from the Danish Trial23 cohort study.
Nonboe MH; Napolitano GM; Kann C; Andersen B; Bennetsen MH; Christiansen S; Frandsen AP; Rygaard C; Salmani R; Schroll JB; Lynge E
PLoS One; 2024; 19(6):e0306044. PubMed ID: 38917143
[TBL] [Abstract][Full Text] [Related]
51. The Aptima HPV assay fulfills the cross-sectional clinical and reproducibility criteria of international guidelines for human papillomavirus test requirements for cervical screening.
Heideman DA; Hesselink AT; van Kemenade FJ; Iftner T; Berkhof J; Topal F; Agard D; Meijer CJ; Snijders PJ
J Clin Microbiol; 2013 Nov; 51(11):3653-7. PubMed ID: 23985912
[TBL] [Abstract][Full Text] [Related]
52. Comparison of the clinical performances of the AdvanSure HPV Screening Real-Time PCR, the Abbott Real-Time High-Risk HPV Test, and the Hybrid Capture High-Risk HPV DNA Test for Cervical Cancer Screening.
Chung HS; Hahm C; Lee M
J Virol Methods; 2014 Sep; 205():57-60. PubMed ID: 24814874
[TBL] [Abstract][Full Text] [Related]
53. Validation of cobas 4800 HPV assay in SurePath Papanicolaou specimens for cervical cancer screening.
Guo M; Shlyakhova N; Khanna A; Tinnirello AA; Schmeler KM; Hwang J; Sturgis EM; Stewart J
J Am Soc Cytopathol; 2021; 10(4):399-405. PubMed ID: 33967024
[TBL] [Abstract][Full Text] [Related]
54. Agreement between the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease.
Carozzi F; Bisanzi S; Sani C; Zappa M; Cecchini S; Ciatto S; Confortini M
J Clin Microbiol; 2007 Feb; 45(2):364-9. PubMed ID: 17122008
[TBL] [Abstract][Full Text] [Related]
55. Prevalence of Human Papillomavirus infection in unselected SurePath samples using the APTIMA HPV mRNA assay.
Rebolj M; Preisler S; Ejegod DM; Bonde J; Rygaard C; Lynge E
J Mol Diagn; 2013 Sep; 15(5):670-7. PubMed ID: 23827659
[TBL] [Abstract][Full Text] [Related]
56. Human papillomavirus messenger RNA assay for cervical cancer screening: the Shenzhen Cervical Cancer Screening Trial I.
Wu R; Belinson SE; Du H; Na W; Qu X; Wu R; Liu Y; Wang C; Zhou Y; Zhang L; Belinson JL
Int J Gynecol Cancer; 2010 Nov; 20(8):1411-4. PubMed ID: 21051986
[TBL] [Abstract][Full Text] [Related]
57. Feasibility and accuracy evaluation of three human papillomavirus assays for FTA card-based sampling: a pilot study in cervical cancer screening.
Wang SM; Hu SY; Chen W; Chen F; Zhao FH; He W; Ma XM; Zhang YQ; Wang J; Sivasubramaniam P; Qiao YL
BMC Cancer; 2015 Nov; 15():848. PubMed ID: 26537356
[TBL] [Abstract][Full Text] [Related]
58. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.
Arbyn M; Roelens J; Simoens C; Buntinx F; Paraskevaidis E; Martin-Hirsch PP; Prendiville WJ
Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD008054. PubMed ID: 23543559
[TBL] [Abstract][Full Text] [Related]
59. The clinical performance of primary HPV screening, primary HPV screening plus cytology cotesting, and cytology alone at a tertiary care hospital.
Choi JW; Kim Y; Lee JH; Kim YS
Cancer Cytopathol; 2016 Feb; 124(2):144-52. PubMed ID: 26457676
[TBL] [Abstract][Full Text] [Related]
60. Aptima HPV Assay versus Hybrid Capture
Cook DA; Smith LW; Law J; Mei W; van Niekerk DJ; Ceballos K; Gondara L; Franco EL; Coldman AJ; Ogilvie GS; Jang D; Chernesky M; Krajden M
J Clin Virol; 2017 Feb; 87():23-29. PubMed ID: 27988420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
